# Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia

**Authors:** Julie A Wolfson, Allison C Grimes, Michelle M Nuño, Subhash Ramakrishnan, David S Dickens, Michael E Roth, Wendy Woods, Kandice S Adams, Tawa Alabi, Melissa Beauchemin, Jennifer M Levine, Michele Scialla, Koh B Boayue, Charlotte L Kerber, Olivia Ponce, Sarah Vargas, George J Chang, Wendy Stock, Dawn Hershman, Emily Curran, Anjali Advani, Kristen O’Dwyer, Selina Luger, Jane Jijun Liu, David R Freyer, Lillian Sung, Susan K Parsons

PMC · DOI: 10.1093/jncics/pkaf033 · JNCI Cancer Spectrum · 2025-04-16

## TL;DR

Young adults with leukemia have better outcomes when treated with pediatric-inspired care, which is more common at certain types of hospitals.

## Contribution

Identifies facility-level factors influencing guideline-concordant care for adolescents and young adults with ALL.

## Key findings

- Guideline-concordant care was nearly universal in patients aged 15-21 years.
- Adult/internal medicine facilities had lower odds of providing guideline-concordant care.
- Communication and clinical pathways improved guideline adherence in mixed facilities.

## Abstract

Individuals diagnosed with acute lymphoblastic leukemia (ALL) between adolescents and young adults aged 15-39 years face poor survival and unique challenges. We evaluated facility-level factors and guideline-concordant care among adolescents and young adults with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices.

We assembled a retrospective cohort of adolescents and young adults aged 15-39 years with ALL treated at participating NCORPs between 2012 and 2016. NCORPs abstracted patient data and completed facility-level questionnaires for each clinical facility (study-defined criteria). The central review committee adjudicated whether treatment was concordant with adolescent and young adult–specific National Comprehensive Cancer Network ALL guidelines (ie, pediatric-inspired therapy or clinical trial). Guideline-concordant care was described by age, facility model (adult/internal medicine, pediatric, mixed [pediatric services within a general hospital]), and average annual adolescents and young adult ALL volume. Generalized linear mixed effects models estimated the odds of guideline-concordant care.

Adolescents and young adults receiving guideline-concordant care were younger (n = 196; median = 19.5 years) than those who did not (n = 31; median = 32.1 years). Guideline-concordant care was observed in many adolescents and young adults aged 22-39 years (68.8%), and nearly universal in those aged 15-21 years. In multivariable analyses, adolescents and young adults at adult/internal medicine clinical facilities had lower odds of guideline-concordant care (odds ratio = 0.02, 95% confidence interval = 0.0 to 0.18); there was no statistically significant association between annual adolescent and young ALL volume and receiving guideline-concordant care. Guideline-concordant care was observed more often in adult/internal medicine and/or mixed clinical facilities with communication between adult or pediatric counterparts, adolescents and young adult ALL clinical pathways, and/or adolescent and young adult–specific meetings.

Guideline-concordant care among adolescents and young adults with ALL (specifically pediatric-inspired therapy) at NCORPs is associated with facility model (adult/internal medicine) but not adolescent and young adult ALL volume. Strategies to improve guideline-concordant care could include facilitating communication and clinical pathways at adult/internal medicine clinical facilities treating adolescent and young adult ALL.

## Linked entities

- **Diseases:** acute lymphoblastic leukemia (MONDO:0004967), ALL (MONDO:0004967)

## Full-text entities

- **Diseases:** ALL (MESH:D054198), Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12121638/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12121638/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12121638/full.md

---
Source: https://tomesphere.com/paper/PMC12121638